Miao Yi, Cao Lei, Sun Qian, Li Xiao-Tong, Wang Yan, Qiao Chun, Wang Li, Wang Rong, Qiu Hai-Rong, Xu Wei, Li Jian-Yong, Wu Yu-Jie, Fan Lei
Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
Hematol Oncol. 2018 Feb;36(1):121-127. doi: 10.1002/hon.2461. Epub 2017 Jul 28.
The incidence of B-cell chronic lymphoproliferative disorders (B-CLPDs) is significantly lower in China than that in western countries. There have been studies involving small cohorts with conflicting results regarding the spectrum of B-CLPDs in China, and the types and immunophenotyping of B-CLPDs in China remain largely unexplored. We conducted a retrospective analysis of 653 cases of B-CLPDs seen in our centre from 2011 to 2015. Four-colour flow cytometry was used to determine the expression of each immunological marker, and the diagnostic values of the immunological markers were also investigated. Chronic lymphocytic leukaemia (CLL) was the most common type of B-CLPD, which was consistent with that in west countries. However, the proportions of CLL (55.9%), follicular lymphoma (2.6%), and hairy cell leukaemia (0.2%) were lower, while the proportion of lymphoplasmacytic lymphoma/WaldenstrÖm macroglobulinaemia (5.4%) was higher in China, as compared with western countries. With respect to immunophenotypic characteristics, CD23 (31.7%) was more frequently expressed in mantle cell lymphoma (MCL) in our cohort than that in western countries. Immunophenotyping was useful in differentiating MCL from CLL or B-cell prolymphocytic leukaemia and lymphoplasmacytic lymphoma/WaldenstrÖm macroglobulinaemia from splenic marginal zone lymphoma. CD200 was of better diagnostic performance (accuracy: 94.6%) in differentiating CLL from MCL compared with CD23 (accuracy: 93.3%). Some cases of B-CPLDs, however, had no definite diagnoses, which were diagnosed as CD5 B-CPLDs unclassified (7.7%) and CD5 B-CPLDs unclassified (15.8%). This is the largest study that systematically explores the spectrum and immunophenotyping of B-CLPDs in Asia, confirming that spectrum of B-CLPDs in China was different from that in western countries. The immunophenotypic features of B-CLPDs were similar between China and western countries, although a few disparities exist. Cases with no definite diagnoses warrant further studies in the future.
中国B细胞慢性淋巴细胞增殖性疾病(B-CLPDs)的发病率显著低于西方国家。已有涉及小样本队列的研究,但关于中国B-CLPDs的谱系结果相互矛盾,中国B-CLPDs的类型和免疫表型仍在很大程度上未被探索。我们对2011年至2015年在本中心就诊的653例B-CLPDs病例进行了回顾性分析。采用四色流式细胞术测定各免疫标志物的表达,并研究免疫标志物的诊断价值。慢性淋巴细胞白血病(CLL)是最常见的B-CLPDs类型,这与西方国家一致。然而,与西方国家相比,中国CLL的比例(55.9%)、滤泡性淋巴瘤的比例(2.6%)和毛细胞白血病的比例(0.2%)较低,而淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的比例(5.4%)较高。关于免疫表型特征,在我们的队列中,套细胞淋巴瘤(MCL)中CD23的表达频率(31.7%)高于西方国家。免疫表型分析有助于将MCL与CLL或B细胞幼淋巴细胞白血病区分开来,以及将淋巴浆细胞淋巴瘤/华氏巨球蛋白血症与脾边缘区淋巴瘤区分开来。与CD23(准确率:93.3%)相比,CD200在区分CLL和MCL方面具有更好的诊断性能(准确率:94.6%)。然而,一些B-CPLDs病例没有明确诊断,被诊断为未分类的CD5 B-CPLDs(7.